KA/EN
Register
Medicines reference
Search
Search
Product

Otimix Plus

Favourites

Miconazole + Polymyxin B + Prednisolone · Bioveta a.s.

1 form: ear drops. In force in Georgia: 1 of 1 (veterinary register).

Forms and doses1 of 1 in force in Georgia

The dose from the product's label, by species and weight. Check the label of the pack you use.

Choose a species; its rows are highlighted.
Form Species Dose Frequency Georgia
Ear drops · Cat Cat 3–5 drops
3-5 drops into the cleaned ear canal twice a day; massage the ear base. Continue a few days after signs resolve: at least 7-10 days, at most 14. Check the eardrum first. On skin: a few drops twice a day to cover the lesion (no count on the label).
 · twice daily, 7-14 days		 twice daily, 7-14 days Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: ოტიმიქსი პლუსი
Verified on: 22 Oct 2026
Ear drops · Dog Dog 3–5 drops
3-5 drops into the cleaned ear canal twice a day; massage the ear base. Continue a few days after signs resolve: at least 7-10 days, at most 14. Check the eardrum first. On skin: a few drops twice a day to cover the lesion (no count on the label).
 · twice daily, 7-14 days		 twice daily, 7-14 days Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: ოტიმიქსი პლუსი
Verified on: 22 Oct 2026
Details: pack, label wording, sources, registration

Otimix Plus, Ear drops

miconazole nitrate 23 mg/ml + polymyxin B sulfate 5500 IU/ml + prednisolone acetate 5 mg/ml, ear drops, suspension for dogs and cats
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Label-concordant topical treatment of limited dermatitis caused by susceptible bacterial/fungal organisms in dogs, with primary dermatosis management
6.6/10
Situational / acceptable
vetman assessment

Otimix Plus

miconazole nitrate 23 mg/ml + polymyxin B sulfate 5500 IU/ml + prednisolone acetate 5 mg/ml, ear drops, suspension for dogs and cats
Assessed clinical scopeDog · Label-concordant topical treatment of limited dermatitis caused by susceptible bacterial/fungal organisms in dogs, with primary dermatosis management · On the skin
Care settingVeterinary skin diagnosis with cytology/culture where indicated, clipping and limited-area twice-daily application with lick prevention and planned recheck
vetman score 6.6/10 Situational / acceptable
Evidence confidence: Low Georgia: Yes, veterinary · Verified on 22 Oct 2026

A plausible labelled option for culture-compatible limited infected dermatitis, but direct skin-outcome evidence is thin and steroid/AMEG-B exposure makes empirical or prolonged use unattractive.

Regulatory and scientific credibility8.0/10

The exact 15 ml dog/cat product has a current national EU regulator record, transparent exact instruction and Georgian registration; it is a generic of an established same-strength combination. Exact independent Otimix outcome/pharmacovigilance data and multi-country dossier breadth are limited.

Clinical efficacy6.0/10

The label and component spectrum support susceptible limited dermatitis, but direct modern canine outcomes for this fixed combination are sparse and broad empirical triple therapy is not justified. Primary allergic/parasitic disease and resistant organisms can defeat apparent short-term improvement.

Safety and tolerability6.0/10

Limited-area short-course exposure is usually manageable, but prednisolone can cause local immunosuppression, epidermal thinning, delayed healing and systemic adrenal effects with extensive, occluded, highly perfused or ingested use. Antimicrobial resistance and hypersensitivity remain.

Clinical practicality6.0/10

Ready-to-use drops and twice-daily limited-area application are workable, but clipping, gloves, full coverage, lick prevention and recheck are required; persistent fungal disease must transition away from steroid, making open-ended home continuation inappropriate.

Full-course cost-effectiveness-

Current Georgian full-course price and pack-wastage data were unavailable; price is excluded from the denominator.

Important safety and use flags

  • Use only on a diagnosed limited susceptible dermatitis. Do not apply to an undiagnosed wound, extensive/ulcerated skin or under an impermeable dressing without a specific monitored plan.
  • Perform cytology and use culture/susceptibility when indicated. Polymyxin B is AMEG category B: reserve it for cases where category C/D antimicrobials are not expected to work; consider cross-resistance with colistin and other imidazoles.
  • Clip as needed, shake, cover the lesion with a few drops twice daily and rub with a gloved hand, generally no more than 14 days. Recheck cure and the underlying disease.
  • Long or extensive corticosteroid exposure can cause local immunosuppression, secondary infection, epidermal thinning, delayed healing, telangiectasia/bleeding and systemic adrenal effects; licking and occlusion increase exposure.
  • For persistent fungal disease beyond the short labelled course, continue with a corticosteroid-free preparation if still indicated; do not prolong prednisolone merely because inflammation rebounds.
  • Otimix Plus is only adjunctive when Otodectes cynotis coexists with susceptible secondary infection. Diagnose and treat mites with an appropriate acaricide and manage all in-contact animals/environment as indicated.
  • Do not use with hypersensitivity to miconazole, polymyxin B, prednisolone or excipients. Pregnancy/lactation safety is unestablished; use only after veterinarian benefit–risk assessment.
  • Treat the primary cause—commonly allergy, parasites, foreign body, conformation or endocrine disease—or recurrence is likely. Steroid-driven relief does not prove microbial eradication.
  • Shake well and prevent dropper contact with ear, skin or fingers. Wear gloves, wash hands and avoid eye/skin contact or ingestion; pregnant or breastfeeding handlers should use particular caution.
  • Store below 25°C and discard three months after first opening. Document opening date, course, organism/susceptibility basis and recheck result; do not keep using a contaminated communal bottle.
Assessment sources
  1. Otimix Czech label2026
  2. Otimix exact instruction2026
  3. Surolan VMD control2025
  4. Surolan Canada control2018
  5. MSD pyoderma2026
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Dog Label-concordant treatment of external otitis caused by susceptible bacterial/fungal organisms in dogs, with intact tympanum and cause-directed management
6.9/10
Situational / acceptable
vetman assessment

Otimix Plus

miconazole nitrate 23 mg/ml + polymyxin B sulfate 5500 IU/ml + prednisolone acetate 5 mg/ml, ear drops, suspension for dogs and cats
Assessed clinical scopeDog · Label-concordant treatment of external otitis caused by susceptible bacterial/fungal organisms in dogs, with intact tympanum and cause-directed management · Into the ear
Care settingVeterinary otoscopy/cytology, intact tympanum confirmation, cleaning and susceptibility-led selection; instructed twice-daily application with massage and planned clinical/cytological recheck
vetman score 6.9/10 Situational / acceptable
Evidence confidence: Medium Georgia: Yes, veterinary · Verified on 22 Oct 2026

An evidence-supported but stewardship-restricted triple ear drop for susceptible external otitis with an intact tympanum. It is useful when diagnostics fit, not a default for every inflamed ear.

Regulatory and scientific credibility8.0/10

The exact 15 ml dog/cat product has a current national EU regulator record, transparent exact instruction and Georgian registration; it is a generic of an established same-strength combination. Exact independent Otimix outcome/pharmacovigilance data and multi-country dossier breadth are limited.

Clinical efficacy7.5/10

Multiple controlled trials of the same three-active combination support canine otitis efficacy, but cure is not universal and modern trials show suitable alternatives can match or outperform it. Activity depends on actual susceptibility, cleaning and correction of primary disease.

Safety and tolerability5.5/10

An intact tympanum is a hard prerequisite because polymyxin B is potentially ototoxic; very rare deafness is reported and steroid/antimicrobial exposure can mask or select persistent infection. Local/systemic corticosteroid effects, hypersensitivity and pregnancy uncertainty remain.

Clinical practicality6.5/10

Three to five drops twice daily for 7–14 days is familiar and feasible after cleaning, but requires reliable home adherence, massage, dropper hygiene and recheck. Otoscopy/intact-tympanum confirmation and AMEG-B susceptibility justification add necessary clinical work.

Full-course cost-effectiveness-

Current Georgian full-course price and pack-wastage data were unavailable; price is excluded from the denominator.

Important safety and use flags

  • Never use unless otoscopy confirms an intact tympanum. Polymyxin B is potentially ototoxic; perforation, suspected middle-ear disease, new vestibular signs or hearing change requires stopping and immediate reassessment.
  • Perform cytology and use culture/susceptibility when indicated. Polymyxin B is AMEG category B: reserve it for cases where category C/D antimicrobials are not expected to work; consider cross-resistance with colistin and other imidazoles.
  • Clean the external canal, shake well, apply 3–5 drops twice daily and massage the base. Treat at least 7–10 and no more than 14 days, with clinical and cytological recheck rather than stopping on appearance alone.
  • Long or extensive corticosteroid exposure can cause local immunosuppression, secondary infection, epidermal thinning, delayed healing, telangiectasia/bleeding and systemic adrenal effects; licking and occlusion increase exposure.
  • Very rare deafness is reported, especially in older dogs. Stop for new hearing loss, head tilt, nystagmus, ataxia or severe pain and investigate otitis media/interna.
  • Otimix Plus is only adjunctive when Otodectes cynotis coexists with susceptible secondary infection. Diagnose and treat mites with an appropriate acaricide and manage all in-contact animals/environment as indicated.
  • Do not use with hypersensitivity to miconazole, polymyxin B, prednisolone or excipients. Pregnancy/lactation safety is unestablished; use only after veterinarian benefit–risk assessment.
  • Treat the primary cause—commonly allergy, parasites, foreign body, conformation or endocrine disease—or recurrence is likely. Steroid-driven relief does not prove microbial eradication.
  • Shake well and prevent dropper contact with ear, skin or fingers. Wear gloves, wash hands and avoid eye/skin contact or ingestion; pregnant or breastfeeding handlers should use particular caution.
  • Store below 25°C and discard three months after first opening. Document opening date, course, organism/susceptibility basis and recheck result; do not keep using a contaminated communal bottle.
Assessment sources
  1. Otimix Czech label2026
  2. Otimix exact instruction2026
  3. Surolan VMD control2025
  4. Surolan Canada control2018
  5. Canine otitis phase III2005
  6. Canine combination trial1991
  7. Burow versus Surolan2021
  8. MSD otitis externa2026
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Label-concordant topical treatment of limited dermatitis caused by susceptible bacterial/fungal organisms in cats, with primary dermatosis management
6.2/10
Situational / acceptable
vetman assessment

Otimix Plus

miconazole nitrate 23 mg/ml + polymyxin B sulfate 5500 IU/ml + prednisolone acetate 5 mg/ml, ear drops, suspension for dogs and cats
Assessed clinical scopeCat · Label-concordant topical treatment of limited dermatitis caused by susceptible bacterial/fungal organisms in cats, with primary dermatosis management · On the skin
Care settingVeterinary skin diagnosis with cytology/culture where indicated, clipping and limited-area twice-daily application with lick prevention and planned recheck
vetman score 6.2/10 Situational / acceptable
Evidence confidence: Low Georgia: Yes, veterinary · Verified on 22 Oct 2026

A weakly evidenced feline skin option whose fixed antibiotic-antifungal-steroid mix, grooming exposure and imprecise lesion dose justify narrow, reassessed use only.

Regulatory and scientific credibility8.0/10

The exact 15 ml dog/cat product has a current national EU regulator record, transparent exact instruction and Georgian registration; it is a generic of an established same-strength combination. Exact independent Otimix outcome/pharmacovigilance data and multi-country dossier breadth are limited.

Clinical efficacy5.5/10

The feline dermatitis indication is regulator-supported, but direct outcome evidence is very limited and grooming increases exposure. Cytology/culture and diagnosis of the primary dermatosis are essential; short-term steroid improvement does not prove infection cure.

Safety and tolerability5.5/10

Skin exposure plus grooming/ingestion increases local and systemic corticosteroid uncertainty in cats. Immunosuppression, delayed healing, secondary infection, resistance and hypersensitivity require a limited area, short course and lick prevention.

Clinical practicality5.5/10

Twice-daily lesion coverage, clipping and lick prevention are difficult in many cats, while an imprecise “few drops” skin dose complicates consistent exposure. Gloves, recheck and switching away from steroid for persistent fungal disease add burden.

Full-course cost-effectiveness-

Current Georgian full-course price and pack-wastage data were unavailable; price is excluded from the denominator.

Important safety and use flags

  • Use only on a diagnosed limited susceptible dermatitis. Do not apply to an undiagnosed wound, extensive/ulcerated skin or under an impermeable dressing without a specific monitored plan.
  • Perform cytology and use culture/susceptibility when indicated. Polymyxin B is AMEG category B: reserve it for cases where category C/D antimicrobials are not expected to work; consider cross-resistance with colistin and other imidazoles.
  • Clip as needed, shake, cover the lesion with a few drops twice daily and rub with a gloved hand, generally no more than 14 days. Recheck cure and the underlying disease.
  • Long or extensive corticosteroid exposure can cause local immunosuppression, secondary infection, epidermal thinning, delayed healing, telangiectasia/bleeding and systemic adrenal effects; licking and occlusion increase exposure.
  • For persistent fungal disease beyond the short labelled course, continue with a corticosteroid-free preparation if still indicated; do not prolong prednisolone merely because inflammation rebounds.
  • Otimix Plus is only adjunctive when Otodectes cynotis coexists with susceptible secondary infection. Diagnose and treat mites with an appropriate acaricide and manage all in-contact animals/environment as indicated.
  • Do not use with hypersensitivity to miconazole, polymyxin B, prednisolone or excipients. Pregnancy/lactation safety is unestablished; use only after veterinarian benefit–risk assessment.
  • Treat the primary cause—commonly allergy, parasites, foreign body, conformation or endocrine disease—or recurrence is likely. Steroid-driven relief does not prove microbial eradication.
  • Shake well and prevent dropper contact with ear, skin or fingers. Wear gloves, wash hands and avoid eye/skin contact or ingestion; pregnant or breastfeeding handlers should use particular caution.
  • Store below 25°C and discard three months after first opening. Document opening date, course, organism/susceptibility basis and recheck result; do not keep using a contaminated communal bottle.
Assessment sources
  1. Otimix Czech label2026
  2. Otimix exact instruction2026
  3. Surolan VMD control2025
  4. Surolan Canada control2018
  5. MSD pyoderma2026
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Label-concordant treatment of external otitis caused by susceptible bacterial/fungal organisms in cats, with intact tympanum and cause-directed management
6.6/10
Situational / acceptable
vetman assessment

Otimix Plus

miconazole nitrate 23 mg/ml + polymyxin B sulfate 5500 IU/ml + prednisolone acetate 5 mg/ml, ear drops, suspension for dogs and cats
Assessed clinical scopeCat · Label-concordant treatment of external otitis caused by susceptible bacterial/fungal organisms in cats, with intact tympanum and cause-directed management · Into the ear
Care settingVeterinary otoscopy/cytology, intact tympanum confirmation, cleaning and susceptibility-led selection; instructed twice-daily application with massage and planned clinical/cytological recheck
vetman score 6.6/10 Situational / acceptable
Evidence confidence: Low Georgia: Yes, veterinary · Verified on 22 Oct 2026

A regulator-supported feline option, but independent feline outcomes are limited and repeated handling plus ototoxicity/stewardship constraints make it conditional.

Regulatory and scientific credibility8.0/10

The exact 15 ml dog/cat product has a current national EU regulator record, transparent exact instruction and Georgian registration; it is a generic of an established same-strength combination. Exact independent Otimix outcome/pharmacovigilance data and multi-country dossier breadth are limited.

Clinical efficacy6.5/10

The exact label includes cats and mixed-species Otodectes plus limited feline reports support the same combination, but independent feline bacterial/fungal otitis outcomes are sparse. The product is only adjunctive for ear mites and susceptibility/primary disease remain decisive.

Safety and tolerability5.5/10

An intact tympanum is a hard prerequisite because polymyxin B is potentially ototoxic; very rare deafness is reported and steroid/antimicrobial exposure can mask or select persistent infection. Local/systemic corticosteroid effects, hypersensitivity and pregnancy uncertainty remain.

Clinical practicality6.0/10

The same small-volume twice-daily regimen is feasible, but many cats resist ear handling for 7–14 days. Safe restraint, cleaning, massage, dropper hygiene, cytological recheck and intact-tympanum confirmation create a meaningful adherence and welfare burden.

Full-course cost-effectiveness-

Current Georgian full-course price and pack-wastage data were unavailable; price is excluded from the denominator.

Important safety and use flags

  • Never use unless otoscopy confirms an intact tympanum. Polymyxin B is potentially ototoxic; perforation, suspected middle-ear disease, new vestibular signs or hearing change requires stopping and immediate reassessment.
  • Perform cytology and use culture/susceptibility when indicated. Polymyxin B is AMEG category B: reserve it for cases where category C/D antimicrobials are not expected to work; consider cross-resistance with colistin and other imidazoles.
  • Clean the external canal, shake well, apply 3–5 drops twice daily and massage the base. Treat at least 7–10 and no more than 14 days, with clinical and cytological recheck rather than stopping on appearance alone.
  • Long or extensive corticosteroid exposure can cause local immunosuppression, secondary infection, epidermal thinning, delayed healing, telangiectasia/bleeding and systemic adrenal effects; licking and occlusion increase exposure.
  • Very rare deafness is reported, especially in older dogs. Stop for new hearing loss, head tilt, nystagmus, ataxia or severe pain and investigate otitis media/interna.
  • Otimix Plus is only adjunctive when Otodectes cynotis coexists with susceptible secondary infection. Diagnose and treat mites with an appropriate acaricide and manage all in-contact animals/environment as indicated.
  • Do not use with hypersensitivity to miconazole, polymyxin B, prednisolone or excipients. Pregnancy/lactation safety is unestablished; use only after veterinarian benefit–risk assessment.
  • Treat the primary cause—commonly allergy, parasites, foreign body, conformation or endocrine disease—or recurrence is likely. Steroid-driven relief does not prove microbial eradication.
  • Shake well and prevent dropper contact with ear, skin or fingers. Wear gloves, wash hands and avoid eye/skin contact or ingestion; pregnant or breastfeeding handlers should use particular caution.
  • Store below 25°C and discard three months after first opening. Document opening date, course, organism/susceptibility basis and recheck result; do not keep using a contaminated communal bottle.
Assessment sources
  1. Otimix Czech label2026
  2. Otimix exact instruction2026
  3. Surolan VMD control2025
  4. Surolan Canada control2018
  5. Dog cat Otodectes trial2000
  6. Feline Malassezia cases2000
  7. MSD otitis externa2026
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Miconazole23 mg/ml Polymyxin B5500 IU/ml Prednisolone5 mg/ml
Formulation Type
Ear drops
Administration route
Into the ear, On the skin
Manufacturer
Bioveta a.s. · Czechia
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: ოტიმიქსი პლუსი
Verified on: 22 Oct 2026
 EU Yes, veterinary
№ CZ 96/053/23-C
Verified on: 22 Oct 2026
 UK No
Verified on: 22 Oct 2026
 US No
Verified on: 22 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 18 Oct 2026
Information not fully verified Shake well. Otitis: after cytology/otoscopy, cleaning and confirmation of intact tympanum, apply 3–5 drops into the affected external canal twice daily and massage; continue a few days after signs resolve, at least 7–10 and at most 14 days. Dermatitis: clip as needed, cover the lesion with a few drops twice daily and rub with a gloved hand, usually no more than 14 days; persistent fungal treatment should continue without corticosteroid. Recheck clinical and cytological cure.
DoseSpeciesWeightRouteFrequencySource
3–5 drops
3-5 drops into the cleaned ear canal twice a day; massage the ear base. Continue a few days after signs resolve: at least 7-10 days, at most 14. Check the eardrum first. On skin: a few drops twice a day to cover the lesion (no count on the label).
 Cat Any weight Into the ear twice daily, 7-14 days
Otimix Czech label
Official product label (SPC)
Approved by a medicines regulator as part of the product's authorisation. It applies to that product as authorised there.
Otimix Plus 23 mg/ml + 5500 IU/ml + 5 mg/ml ear drops suspension - current Czech authorisation record
EU Veterinary Medicines Information / Union Product Database, 2026
3–5 drops
3-5 drops into the cleaned ear canal twice a day; massage the ear base. Continue a few days after signs resolve: at least 7-10 days, at most 14. Check the eardrum first. On skin: a few drops twice a day to cover the lesion (no count on the label).
 Dog Any weight Into the ear twice daily, 7-14 days
Otimix Czech label
Official product label (SPC)
Approved by a medicines regulator as part of the product's authorisation. It applies to that product as authorised there.
Otimix Plus 23 mg/ml + 5500 IU/ml + 5 mg/ml ear drops suspension - current Czech authorisation record
EU Veterinary Medicines Information / Union Product Database, 2026
Active substance doses, with sources
Active substance Prednisolone
Dose calculatorCalculates the active-substance amount; it is not a prescription.
PatientSpecies and weight will be filled in automatically in other calculators.
Selected dose
Dose Species Indication Route Frequency Source
0.1–2 mg/kg Dog, Cat Inflammation By mouth once daily
VMD SPC 2026
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Prednicare 5 mg Tablets - Summary of Product Characteristics
UK Veterinary Medicines Directorate, Product Information Database, 2026
0.5–4 mg/kg Dog, Cat Immune-Mediated Disease By mouth once daily
VMD SPC 2025
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Prednicortone 5 mg Tablets for Dogs and Cats - Summary of Product Characteristics
UK Veterinary Medicines Directorate, Product Information Database, 2025
0.5–1 mg/kg Dog, Cat Inflammation Intramuscular Single dose
VMD SPC 2023
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Cortico Veyxin 10 mg/ml Suspension for Injection - Summary of Product Characteristics
UK Veterinary Medicines Directorate, Product Information Database, 2023

Miconazole: No dose supported by a publicly verifiable source yet

Polymyxin B: No dose supported by a publicly verifiable source yet

Known Contraindications

  • Critical Miconazole
    Do not use if hypersensitive to miconazole or other azole antifungals.
    Sources: UK SPC
  • Critical Polymyxin B
    Do not use if hypersensitive to polymyxin B.
  • Critical Prednisolone
    An uncontrolled viral, fungal, or parasitic infection is an absolute contraindication. The parasitic-infection restriction is specified on the Prednicare label.
  • Critical Prednisolone
    Diabetes mellitus is an absolute contraindication on the Prednicare and Prednicortone labels.
    Sources: Product label
  • Critical Prednisolone
    Hyperadrenocorticism is an absolute contraindication on the Prednicare and Prednicortone labels.
    Sources: Product label
  • Critical Prednisolone
    Osteoporosis is an absolute contraindication on the Prednicare and Prednicortone labels.
    Sources: Product label
  • Critical Prednisolone
    Corneal ulceration is an absolute contraindication on the Prednicare and Prednicortone labels.
    Sources: Product label
  • Critical Prednisolone
    Glaucoma is an absolute contraindication on the Prednicare and Prednicortone labels.
    Sources: Product label
  • Critical Prednisolone
    Hypersensitivity to prednisolone or any excipient is an absolute contraindication on the Prednicare and Prednicortone labels.
    Sources: Product label
  • Critical Prednisolone
    Burn injury is listed as a contraindication on the Prednicortone label but not on the other two reviewed labels.
    Sources: Product label
  • Critical Prednisolone
    Cataract is listed as a contraindication on the Cortico Veyxin label.
    Sources: Product label
  • Critical Prednisolone
    Hypocalcaemia is listed as a contraindication on the Cortico Veyxin label.
    Sources: Product label
  • Critical Prednisolone
    Hypertension is listed as a contraindication on the Cortico Veyxin label.
    Sources: Product label
  • Critical Prednisolone
    Pancreatitis is listed as a contraindication on the Cortico Veyxin label.
    Sources: Product label
  • Critical Prednisolone
    A poorly healing wound or fracture is listed as a contraindication on the Cortico Veyxin label.
    Sources: Product label
  • Critical Prednisolone
    General immunodeficiency is listed as a contraindication on the Cortico Veyxin label.
    Sources: Product label
  • Critical Prednisolone
    Gastrointestinal ulceration is an absolute contraindication on all three reviewed labels. Concomitant corticosteroid and NSAID treatment further increases the risk of ulceration; see the interaction warnings.
    Sources: Product label
  • Critical Prednisolone
    cardiac or renal dysfunction
    Sources: Product label
  • Critical Prednisolone
    Severe renal impairment is an absolute contraindication on the Prednicare label.
    Sources: Product label
  • Critical Prednisolone
    Do not use during pregnancy. Some corticosteroid products specify this restriction for the final third of gestation.
  • Warning Prednisolone
    Use in growing animals carries a risk of growth retardation, suppression of bone growth, and damage to the bone matrix.
  • Warning Prednisolone
    Do not use with a live attenuated vaccine because corticosteroids suppress the immune response to vaccination. The Prednicortone label also prohibits use within 2 weeks after vaccination.
  • Warning Prednisolone
    very rare

Known Drug Interactions

  • Contraindicated Meloxicam + Prednisolone
    Concomitant use of corticosteroids and non-steroidal anti-inflammatory drugs can worsen gastrointestinal ulceration.
    Recommendation: Do not administer together. Observe an appropriate washout period when switching and monitor for melena, vomiting, and reduced appetite.
    Sources: Product label
  • Contraindicated Robenacoxib + Prednisolone
    Do not give robenacoxib together with other non-steroidal anti-inflammatory drugs or glucocorticoids because adverse gastrointestinal and renal effects may increase.
    Recommendation: Do not use these drugs together. Allow a treatment-free interval of at least 24 hours after the previous anti-inflammatory drug, extending it when required by that drug’s pharmacokinetics.
  • Major warning Prednisolone + Insulin glargine
    Glucocorticoids, progestogens, and certain endocrinopathies can have an antagonistic effect on insulin activity. Glucocorticoid and progestogen use should be avoided.
    Recommendation: Avoid the combination. If the glucocorticoid cannot be discontinued within 2 weeks, the insulin dose may need to be increased; monitor glycaemia.
    Sources: FDA · AAHA
  • Major warning Prednisolone + Insulin human
    Glucocorticoids, progestogens, and certain endocrinopathies can have an antagonistic effect on insulin activity. Glucocorticoid and progestogen use should be avoided.
    Recommendation: Avoid the combination. If the glucocorticoid cannot be discontinued within 2 weeks, the insulin dose may need to be increased; monitor glycaemia.
    Sources: FDA · AAHA
  • Major warning Furosemide + Prednisolone
    Concurrent use with drugs affecting electrolyte balance (corticosteroids, other diuretics, amphotericin B, cardiac glycosides) requires careful monitoring.
    Recommendation: Monitor electrolytes, particularly potassium. Check periodically during prolonged combination therapy.
    Sources: VMD SPC · VMD
  • Major warning Carprofen + Prednisolone
    Do not give other non-steroidal anti-inflammatory drugs or glucocorticoids concurrently with carprofen or within 24 hours of treatment because gastrointestinal ulceration or perforation may occur.
    Recommendation: Consider appropriate washout times when switching from one NSAID to another or when switching from corticosteroid use to NSAID use.
    Sources: FDA

Products are connected by name, active ingredients, or therapeutic group. They are not direct substitutes for one another.

Show all related products (31 more) Hide additional products

Same therapeutic group 31

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 23 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Register Demo ↗